Tenax Therapeutics (TENX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 117,976 | 118,755 | 97,565 | 99,369 | 105,462 |
| Other current assets | 272 | 107 | 1,019 | 0 | 0 |
| TOTAL | $121,663 | $123,178 | $104,227 | $102,810 | $105,857 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $121,663 | $123,178 | $104,227 | $102,810 | $105,857 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,795 | 6,346 | 6,041 | 5,608 | 562 |
| Accrued Expenses | 1,278 | 2,140 | 1,115 | 991 | 1,965 |
| TOTAL | $8,073 | $8,486 | $7,156 | $6,599 | $2,527 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $8,073 | $8,486 | $7,156 | $6,599 | $2,527 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 37,424 | 26,525 | 17,198 | 6,244 | 4,563 |
| Common Shares | 3 | 2 | 1 | 1 | N/A |
| Retained earnings | -400,973 | -383,170 | -367,454 | -351,914 | -336,110 |
| TOTAL | $113,590 | $114,692 | $97,071 | $96,211 | $103,330 |
| Total Liabilities And Equity | $121,663 | $123,178 | $104,227 | $102,810 | $105,857 |